强生
JNJ207.640USD
-0.140-0.07%
收盘 12/26, 16:00（美东）报价延迟15分钟
499.62B总市值
19.90市盈率 TTM
关于 强生 公司
强生公司（Johnson & Johnson）通过旗下子公司，专注医疗健康领域产品的研发、生产与全球行销。公司聚焦提升人类健康与福祉，并分为 「Innovative Medicine（创新医药）」与「J&J MedTech（医疗科技）」 两大业务 。 Innovative Medicine 深耕免疫学、传染病、神经科学、肿瘤学、肺动脉高压、心血管和代谢疾病等治疗领域。医疗科技部门提供骨科、外科、介入治疗、心血管介入与视觉保健等产品，并因收购 Shockwave Medical 将其商用血管内碎石术 (IVL) 平台纳入，用于 CAD 与 PAD 的微创治疗 ；同时研发数据驱动的外科机器人与数位手术解决方案。
强生简介
公司代码JNJ
公司名称Johnson & Johnson
上市日期Oct 31, 2080
CEODuato (Joaquin Boix)
员工数量138100
证券类型Ordinary Share
年结日Oct 31
公司地址One Johnson & Johnson Plaza
城市NEW BRUNSWICK
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编08933
电话17325242455
网址https://www.jnj.com/
公司代码JNJ
上市日期Oct 31, 2080
CEODuato (Joaquin Boix)
强生公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
12.85K
+17.90%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
--
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Oncology-DARZALEX
3.54B
14.91%
Immunology-STELARA
1.65B
6.96%
Cardiovascular-ELECTROPHYSIOLOGY
1.47B
6.18%
Surgery-General
1.39B
5.86%
Immunology-TREMFYA
1.19B
5.00%
其他
14.51B
61.10%
地区USD
名称
营收
占比
United States
13.54B
57.04%
Europe
5.39B
22.69%
Asia-Pacific, Africa
3.61B
15.19%
Western Hemisphere, excluding U.S.
1.21B
5.08%
业务
地区
业务USD
名称
营收
占比
Oncology-DARZALEX
3.54B
14.91%
Immunology-STELARA
1.65B
6.96%
Cardiovascular-ELECTROPHYSIOLOGY
1.47B
6.18%
Surgery-General
1.39B
5.86%
Immunology-TREMFYA
1.19B
5.00%
其他
14.51B
61.10%
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.78%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
其他
75.51%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.78%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
其他
75.51%
股东类型
持股股东
占比
Investment Advisor
39.47%
Investment Advisor/Hedge Fund
24.27%
Research Firm
3.15%
Pension Fund
2.24%
Bank and Trust
2.16%
Insurance Company
1.61%
Sovereign Wealth Fund
1.41%
Hedge Fund
0.72%
Family Office
0.09%
其他
24.88%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
5885
1.79B
74.44%
+16.50K
2025Q2
5920
1.78B
73.89%
-7.65M
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
236.03M
9.8%
+3.04M
+1.31%
Jun 30, 2025
State Street Investment Management (US)
132.80M
5.51%
-992.45K
-0.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
129.76M
5.39%
+619.12K
+0.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
60.61M
2.52%
+1.23M
+2.06%
Jun 30, 2025
JP Morgan Asset Management
36.71M
1.52%
+1.46M
+4.13%
Jun 30, 2025
State Farm Insurance Companies
34.37M
1.43%
--
--
Jun 30, 2025
Norges Bank Investment Management (NBIM)
31.93M
1.33%
+1.57M
+5.18%
Jun 30, 2025
Wellington Management Company, LLP
24.88M
1.03%
+2.23M
+9.85%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
25.30M
1.05%
+1.23M
+5.13%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
19.85M
0.82%
+148.42K
+0.75%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares U.S. Pharmaceuticals ETF
23.7%
VanEck Pharmaceutical ETF
10.06%
FT Vest DJIA Dogs 10 Target Income ETF
9.82%
Health Care Select Sector SPDR Fund
9.32%
Proshares Ultra Health Care
9%
iShares U.S. Healthcare ETF
8.9%
JPMorgan Healthcare Leaders ETF
8.38%
First Trust NASDAQ Pharmaceuticals ETF
8.28%
Fidelity MSCI Health Care Index ETF
7.67%
Franklin Income Focus ETF
7.08%
查看更多
iShares U.S. Pharmaceuticals ETF
占比23.7%
VanEck Pharmaceutical ETF
占比10.06%
FT Vest DJIA Dogs 10 Target Income ETF
占比9.82%
Health Care Select Sector SPDR Fund
占比9.32%
Proshares Ultra Health Care
占比9%
iShares U.S. Healthcare ETF
占比8.9%
JPMorgan Healthcare Leaders ETF
占比8.38%
First Trust NASDAQ Pharmaceuticals ETF
占比8.28%
Fidelity MSCI Health Care Index ETF
占比7.67%
Franklin Income Focus ETF
占比7.08%
分红派息
近5年累计派现
56.79B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
强生的前五大股东是谁？
强生 的前五大股东如下：
The Vanguard Group, Inc.持有股份：236.03M，占总股份比例：9.80%。
State Street Investment Management (US)持有股份：132.80M，占总股份比例：5.51%。
BlackRock Institutional Trust Company, N.A.持有股份：129.76M，占总股份比例：5.39%。
Geode Capital Management, L.L.C.持有股份：60.61M，占总股份比例：2.52%。
JP Morgan Asset Management持有股份：36.71M，占总股份比例：1.52%。
The Vanguard Group, Inc.持有股份：236.03M，占总股份比例：9.80%。
State Street Investment Management (US)持有股份：132.80M，占总股份比例：5.51%。
BlackRock Institutional Trust Company, N.A.持有股份：129.76M，占总股份比例：5.39%。
Geode Capital Management, L.L.C.持有股份：60.61M，占总股份比例：2.52%。
JP Morgan Asset Management持有股份：36.71M，占总股份比例：1.52%。
强生的前三大股东类型是什么？
强生 的前三大股东类型分别是：
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
有多少机构持有强生(JNJ)的股份？
截至2025Q3，共有5885家机构持有强生的股份，合计持有的股份价值约为1.79B，占公司总股份的74.44%。与2025Q2相比，机构持股有所增加，增幅为0.55%。
哪个业务部门对强生的收入贡献最大？
在FY2025Q2，Oncology-DARZALEX业务部门对强生的收入贡献最大，创收3.54B，占总收入的14.91%。
